Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

M D Feher, J Foxton, D Banks, A F Lant, R Wray

Abstract

Objective—To evaluate the long-term safety profile of treatment with a statin-fibrate combination in a cohort of patients with documented coronary artery disease.

Design—Retrospective cohort analytical study.

Setting—District general hospital.

Patients—102 (81 male and 21 female) hypercholesterolaemic (total cholesterol concentration > 6·5 mmol/l) patients with documented coronary artery disease and who had been treated with a statin-fibrate combination for over 1 year. Coronary artery disease was confirmed by angiography in 93 patients and by a positive (Bruce protocol) exercise test in the remainder. Fifty eight patients had a history of previous coronary bypass graft surgery.

Interventions—Twice daily lipid lowering treatment was given, with the fibrate administered in the morning (either bezafibrate 400 mg (n = 101) or fenofibrate 200 mg (n = 1)) and the statin in the evening (either simvastatin 10 mg (n = 23), 20 mg (n = 72), or 40 mg (n = 2) or pravastatin 10 mg (n = 1) or 20 mg (n = 4)). Treatment continued for 1 (n = 9), 2 (n = 58), or 3 (n = 35) years.

Main outcome measures—Selected laboratory variables (total cholesterol concentration and liver (aspartate transaminase (AST)) and muscle enzyme (creatine kinase (CK)) activities) and documented symptomatology.

Results—A mean (SD) total cholesterol concentration of 5·2 (0·8) mmol/l was achieved after combined treatment for 1 year which was maintained at annual follow up. Over a maximum 3 year follow up no patient reported myalgic symptoms and none had a measured CK activity > 10 times above normal. Fourteen patients with a negative history of alcohol excess (consumption < 21 units/week) had borderline raised AST values.

Conclusions—Statin-fibrate combination treatment for up to 3 years in a cohort of patients with coronary artery disease was not associated with serious disturbances in biochemical markers of muscle or liver function.

(Br Heart J 1995;74:14–17)

Keywords: statin-fibrate combination therapy; hypercholesterolaemia; coronary artery disease

Increasing evidence from secondary prevention trials confirms that effective cholesterol lowering retards progression of coronary atherosclerosis in patients with established coronary artery disease.1,2 Lower cholesterol concentrations are consequently considered desirable in these patients to reduce the exaggerated risk of subsequent coronary events.3,4 Combination treatment with different hypolipidaemic drug groups has been shown to enhance cholesterol lowering5 and may have a useful role in achieving this therapeutic target in such high risk patients.

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor or statin group of drugs are the most potent hypcholesterolaemic agents currently available and are generally well tolerated.6 Complications reported with statin treatment include increases in muscle and liver enzyme activities, with rare individual cases of myositis (defined as creatine kinase (CK) activity > 10 times above normal) and rhabdomyolysis when statins have been given in combination with other drugs including cyclosporin and the fibric acid derivative gemfibrozil.7 The potential hazards reported in these individual cases have had a negative influence on the widespread use of statin in combination with other fibric acid derivatives. The aim of this study was to evaluate the long-term safety profile of treatment with a statin-fibrate combination in a cohort of patients with documented coronary artery disease.

Patients and methods

A total of 102 (81 male and 21 female) hypercholesterolaemic (defined as initial total cholesterol concentration > 6·5 mmol/l) patients with documented coronary artery disease and who had been treated with a statin-fibrate combination for over 1 year were studied. Twice daily treatment was given, with the fibrate
Results

Of the cohort of 102 patients, safety data were collected prospectively over a 3 year treatment period in 35, over 2 years in 58 and over 1 year in nine. For the whole group, the pretreatment mean (SD) serum total cholesterol concentration of 7-4 (1-6) mmol/l was reduced to 5-2 (0-8) mmol/l after combination drug treatment for 1 year. This reduction in total cholesterol was maintained at the 2 and 3 year follow up.

Over a maximum 3 year follow up no patient reported myalgic symptoms and none had increased plasma CK activity 10 times above normal. Four male patients treated with a simvastatin-bezafibrate combination had an increase in CK activity above the reference range (table 1). Peak CK values were observed in two of these patients (958 and 618 U/l) after treatment for 1 year, in the third patient at 2 years (418 U/l) and in the fourth at 3 years (451 U/l). Fourteen patients despite a negative history of alcohol excess (consumption < 21 units/week) had borderline raised AST values but none had significant disturbances in CK activity (table 2).

Discussion

Statin drugs are widely prescribed for the treatment of hypercholesterolaemia due to their established cholesterol lowering efficacy and tolerability. However, information from long-term usage in prospective randomised trials of statins is only just emerging. 2 Simvastatin has been shown to achieve 70% of its lipid lowering effect at low dose, 9 hence a further increase in dosage may not enhance substantially cholesterol lowering, but may be associated with the hazard of dose dependent adverse effects.

Current consensus guidelines in Britain recommend a desirable cholesterol concentration of < 5-2 mmol/l in patients at highest risk of vascular disease, in particular those with established coronary artery disease. 1 The use of combination lipid lowering treatment is often required to achieve this goal, and has clearly been shown to enhance cholesterol lowering. 11 12 Most regimens have excluded the combination of a fbrate with a statin due to individual case reports of muscle toxicity. 7 8 Nicotinic acid derivatives or bile acid sequestrants have been the main choice as partners to statins in combination treatment but widespread use is often limited because of adverse gastrointestinal effects particularly for the bile acid sequestrants, while rash, flushing and rarely myopathy have been reported with nicotinic acid. 9 Additionally, hypertriglyceridaemia is a well documented side effect of bile acid sequestrants 11 which would mitigate their inclusion in the management of patients with a mixed hyperlipidaemia.

Reports of greatly increased plasma CK activity and rhabdomyolysis with statin treatment have included patients who have been organ transplant recipients necessitating the co-administration of the immunosuppressive agent cyclosporin. 13 14 There is clear

Table 1  Details of four male patients with an increase in creatine kinase (CK) above normal range (< 374 U/l)

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Treatment duration (year)</th>
<th>Alcohol (units/week)</th>
<th>Dosage (mg)</th>
<th>No of patients</th>
<th>CK (U/l) (NR: M &lt; 374; F &lt; 230)</th>
<th>AST (U/l) (NR: 5-40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>63</td>
<td>F</td>
<td>3</td>
<td>0</td>
<td>Bezafibrate 400</td>
<td>4</td>
<td>83</td>
<td>67</td>
</tr>
<tr>
<td>2</td>
<td>52</td>
<td>M</td>
<td>2</td>
<td>0</td>
<td>Bezafibrate 20</td>
<td>2</td>
<td>175</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>63</td>
<td>M</td>
<td>2</td>
<td>12</td>
<td>Simvastatin 70</td>
<td>1</td>
<td>75</td>
<td>73</td>
</tr>
<tr>
<td>4</td>
<td>70</td>
<td>M</td>
<td>3</td>
<td>6</td>
<td>Simvastatin 50</td>
<td>2</td>
<td>20</td>
<td>68</td>
</tr>
<tr>
<td>5</td>
<td>60</td>
<td>M</td>
<td>3</td>
<td>20</td>
<td>Simvastatin 60</td>
<td>1</td>
<td>93</td>
<td>58</td>
</tr>
<tr>
<td>6</td>
<td>77</td>
<td>M</td>
<td>3</td>
<td>20</td>
<td>Pravastatin 77</td>
<td>3</td>
<td>0</td>
<td>97</td>
</tr>
<tr>
<td>7</td>
<td>57</td>
<td>M</td>
<td>3</td>
<td>0</td>
<td>Pravastatin 57</td>
<td>1</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>8</td>
<td>73</td>
<td>M</td>
<td>1</td>
<td>10</td>
<td>Pravastatin 73</td>
<td>5</td>
<td>20</td>
<td>46</td>
</tr>
<tr>
<td>9</td>
<td>59</td>
<td>M</td>
<td>3</td>
<td>12</td>
<td>Pravastatin 59</td>
<td>2</td>
<td>196</td>
<td>45</td>
</tr>
<tr>
<td>10</td>
<td>60</td>
<td>M</td>
<td>3</td>
<td>0</td>
<td>Pravastatin 60</td>
<td>3</td>
<td>0</td>
<td>97</td>
</tr>
<tr>
<td>11</td>
<td>55</td>
<td>F</td>
<td>2</td>
<td>10</td>
<td>Pravastatin 55</td>
<td>1</td>
<td>0</td>
<td>72</td>
</tr>
<tr>
<td>12</td>
<td>61</td>
<td>M</td>
<td>2</td>
<td>10</td>
<td>Pravastatin 61</td>
<td>2</td>
<td>10</td>
<td>24</td>
</tr>
<tr>
<td>13</td>
<td>43</td>
<td>M</td>
<td>2</td>
<td>21</td>
<td>Pravastatin 43</td>
<td>2</td>
<td>21</td>
<td>24</td>
</tr>
<tr>
<td>14</td>
<td>62</td>
<td>M</td>
<td>2</td>
<td>0</td>
<td>Pravastatin 62</td>
<td>1</td>
<td>0</td>
<td>233</td>
</tr>
</tbody>
</table>

NR, normal range.

Table 2  Alcohol consumption and plasma creatine kinase (CK) activities in 14 patients treated with statin-fibrate combination treatment who developed plasma activities of AST > 40 U/l
evidence of a pharmacokinetic interaction with this drug combination resulting in a fivefold increase in circulating statin concentrations. However a profound rise in CK values with lovastatin treatment has been observed rarely in the absence of immunosuppressive treatment.

This finding has also been reported for lovastatin given with either nicotinic acid or gemfibrozil. In most cases where there were clinical features of myositis or rhabdomyolysis, lovastatin had been the prescribed statin. By comparison, there are no cases using other statins and there has been only one report of an association with low dose simvastatin, with the adverse event occurring 3 months after the start of treatment.

The recent evidence that untreated hypercholesterolaemic patients may have increased muscle enzyme activities, both before and after exercise (JWA Smit et al, 62nd European Atherosclerosis Society meeting, Jerusalem, Israel, 1993) highlights the difficulties in attributing a single causative role to statin or fibrate drugs (either singularly or in combination) in initiating the altered muscle biochemistry.

There have been reports of transient increases in serum liver transaminases with fibrate treatment and up to three times normal values in about 1-5% of patients treated with statins. There are few data, however, on the numbers of patients withdrawn from such treatment because of this adverse effect. It is of interest in the present study in which both drug groups were used in combination that only one patient had an increase of three times the upper normal AST activity and the remaining patients had only borderline changes in AST values.

Cholesterol lowering effects of combined statin-fibrate treatment in different types of hyperlipidaemia have been previously studied (H. Vanhanen et al, international symposium on atherosclerosis, Illinois, United States, 1991; K. Takata et al, 11th international symposium on drugs affecting lipid metabolism, Florence, Italy, 1992; R. Volpe et al, 62nd European Atherosclerosis Society meeting on familial hypercholesterolaemia, Jerusalem, Israel, 1993). Most patients had been treated for less than 10 months, (H Vanhanen et al, international symposium on atherosclerosis; K Takata et al, 11th international symposium on drugs affecting lipid metabolism, Florence, Italy, 1992; R Volpe et al, 62nd European Atherosclerosis Society meeting on familial hypercholesterolaemia, Jerusalem, Israel, 1993). While two reports included patients treated for up to 18 months.

No study reported exclusively on patients with documented coronary artery disease. These short-term studies in patients without confirmed coronary disease but who had either hypercholesterolaemia or a mixed hyperlipidaemia used treatment combinations of clofibrate, bezafibrate (K Takata et al, 11th international symposium on drugs affecting lipid metabolism, Florence, Italy, 1992).
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.

M. D. Feher, J. Foxton, D. Banks, A. F. Lant and R. Wray

Br Heart J 1995 74: 14-17
doi: 10.1136/hrt.74.1.14

Updated information and services can be found at:
http://heart.bmj.com/content/74/1/14

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/